Background and Aims: Hyperglycemia has been linked to adverse outcomes in COVID-19 patients, and poor glycemic control may contribute to a higher risk of poor outcomes and death in COVID-19 patients. We hypothesise that hyperglycemia may contribute greatly to COVID-19 mortality, and we aim to assess the association between hyperglycemia and mortality in critically ill COVID-19 patients. Methods: This retrospective study included sixty COVID-19 patients admitted to the COVID-19 ICU from July 2020 to July 2021. Patients were divided into four groups based on random blood sugar at admission to the COVID-19 ICU. The number of deaths in each group was recorded. The data collected was analysed using the statistical package SPSS version 15.0 (SPSS Inc., Chicago, 1L), and a Fisher exact test was performed to find out the association between hyperglycemia and mortality in critically ill COVID-19 patients. Results: The frequency and percentage of mortality in various groups were derived based on random blood sugar on admission to the COVID-19 ICU. The Fisher exact test showed no significant association between the random blood sugar level and mortality in critically ill COVID-19 patients (P > 0.001). The frequency and percentage of the demographic profile of the participants (N = 60) were obtained, and the median + SD age in years was 48 + 16. Conclusion: Among the sixty patients who were investigated, 58.3 percent of them survived, and our study showed no significant association between random blood sugar levels and mortality in critically ill COVID-19 patients.